Credit Agricole S A Sells 3,936 Shares of Solventum Corporation $SOLV

Key Points

• Credit Agricole S A has reduced its stake in Solventum Corporation by 20.9%, selling 3,936 shares and holding 14,914 shares valued at approximately $1.13 million.
• Solventum's quarterly earnings exceeded expectations, reporting $1.69 earnings per share, significantly higher than the consensus estimate of $1.45.
• Recent analyst reports show mixed ratings for Solventum, with one analyst downgrade from "strong-buy" to "buy" and others adjusting price targets between $79.00 and $103.00.

Credit Agricole S A cut its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 20.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,914 shares of the company's stock after selling 3,936 shares during the quarter. Credit Agricole S A's holdings in Solventum were worth $1,134,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Banco Bilbao Vizcaya Argentaria S.A. purchased a new stake in Solventum during the first quarter valued at about $226,000. Hsbc Holdings PLC lifted its holdings in Solventum by 0.8% during the first quarter. Hsbc Holdings PLC now owns 260,225 shares of the company's stock valued at $19,725,000 after purchasing an additional 2,009 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Solventum by 1.0% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 56,806 shares of the company's stock valued at $4,319,000 after purchasing an additional 572 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Solventum by 226.2% during the first quarter. Wellington Management Group LLP now owns 27,737 shares of the company's stock valued at $2,109,000 after purchasing an additional 19,233 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Solventum by 3.3% in the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock worth $137,456,000 after buying an additional 58,373 shares in the last quarter.

Solventum Stock Up 2.0%

SOLV stock opened at $73.46 on Monday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The company's 50 day moving average is $73.79 and its 200 day moving average is $72.84. The stock has a market cap of $12.74 billion, a price-to-earnings ratio of 34.01, a price-to-earnings-growth ratio of 1.78 and a beta of 0.52. Solventum Corporation has a 1-year low of $59.35 and a 1-year high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.24. The company had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. Solventum's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Solventum from a "strong-buy" rating to a "buy" rating in a report on Sunday. Wells Fargo & Company increased their price target on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Argus upgraded shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Finally, Piper Sandler restated an "overweight" rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $85.75.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.